$0.3200
-1.07-76.98%
Last update: Nov 10, 3:59 PM
GLUCOTRACK INC NEW by GlucoTrack, Inc.
GCTKOTCPK
GLUCOTRACK INC NEW by GlucoTrack fell 99.6% from $83.40 to $0.32, behind the S&P 500's +10.0%. Its worst day was Nov 5 (−72.7%), and its low came Nov 6 at $0.30.
Nov 10, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-69.60 was reported on $0.00 revenue.
−8.6% · S&P 500 0.0%
GLUCOTRACK INC NEW by GlucoTrack closed at its highest level of the year, 22.3% above where the year started.
Story events cover the past 12 months · Times ET
+6.9% · S&P 500 +0.5%
EPS of $-59.55 was reported on $0.00 revenue.
−14.1% · S&P 500 +2.9%
EPS of $-39.75 was reported on $0.00 revenue.
−3.0% · S&P 500 −1.2%
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc.
+173.7%, the year's best day · S&P 500 +1.7%
EPS of $-11.40 was reported on $0.00 revenue.
−6.9% · S&P 500 −0.5%
GLUCOTRACK INC NEW by GlucoTrack shares rose 99.7%, while the S&P 500 rose 0.7%.
+99.7% · S&P 500 +0.7%
GLUCOTRACK INC NEW by GlucoTrack shares fell 72.7%, while the S&P 500 fell 4.4%.
−72.7%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $0.32 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All GCTK analyst actionsNothing in the past 12 months.
All GCTK dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GCTK and SPY from Benzinga historical bars. Not investment advice.
